Market+ (iPhone)

Market+ (Android)

US STOCKS

FUNDS

FX & CRYPTO

SH/SZ-HK

HK STOCKS

IPO Plus - IPO

To-be Listed

	Name▼ / Code▼	Industry	Offer Price	Lot Size	Entry Fee	Closing Date	Grey Market Date▼	Listing Date▲
	REFIRE 02570.HK	Electrical Components & Equipment	145-165	20	3,333	2024/12/03	2024/12/05	2024/12/06
	Dmall 02586.HK	Application Software	30.21	100	N/A	2024/12/03	2024/12/05	2024/12/06

Summary

We are a leading ophthalmic medical service group in North China with a strong reputation nationwide. According to the Frost & Sullivan Report, we ranked first in Inner Mongolia, second in North China and fifth in China among private ophthalmic hospitals in terms of total revenue in 2020. China is a large and fast growing market for ophthalmic medical services. According to the Frost & Sullivan Report, the size of the ophthalmic medical services market in China increased from RMB73.0 billion in 2015 to RMB127.5 billion in 2019, representing a CAGR of 15.0%, and is expected to further grow to RMB223.1 billion in 2024; the size of the ophthalmic medical services market in North China increased from RMB13.2 billion in 2015 to RMB21.2 billion in 2019, representing a CAGR of 12.5%, and is expected to further grow to RMB33.7 billion in 2024; the size of the ophthalmic medical services market in Inner Mongolia increased from RMB1.1 billion in 2015 to RMB2.0 billion in 2019, representing a CAGR of 15.6%, and is expected to further grow to RMB3.3 billion in 2024. With an increasing population with high demands for ophthalmic medical services, it is expected that the ophthalmic medical services market in China has great potential for further growth. Leveraging our experience in ophthalmic services and market leading position, we believe we are well-positioned to capture the growing opportunities and benefit from the rapid expansion of the ophthalmic services market in the PRC. We were founded in 1988 in Baotou, Inner Mongolia, where Mr. Zhang Chaoju, a pioneer of modern ophthalmology in Inner Mongolia and an entrepreneur in the field of ophthalmic services in China, founded the predecessor of our Company, a clinic providing ophthalmic services. The Zhang’s family is a medical family with a century’s heritage. Since our inception, we have adhered to the vision of “taking our century’s heritage to bring light to the world and inspire hope” (百年朝聚，朝向光明，聚集希望) and provided patients with safe, reassuring and affordable ophthalmic medical experience with professional and effective equipment and technology as well as caring and considerate services. With a deep root in North China, we have built a broad network of ophthalmic hospitals and optical centers spanning across five provinces or autonomous region in China, namely, Inner Mongolia, Zhejiang Province, Jiangsu Province, Shanxi Province and Hebei Province. As of the Latest Practicable Date, we operated a network of 17 ophthalmic hospitals and 23 optical centers. In addition, as of the Latest Practicable Date, we also operated two clinics as branches of our hospitals, and one of our optical centers also held a medical institution practicing certificate and was licensed to operate as a clinic providing certain out-patient services. We generate revenue primarily from (i) consumer ophthalmic services and (ii) basic ophthalmic services. We classify our ophthalmic services primarily based on the type of disorders and diseases treated, type of treatments provided, eligibility for public health insurance program coverage and the generally accepted practice in the ophthalmic services industry. Our consumer ophthalmic services include treatments and prevention of various types of ophthalmic disorders, including refractive correction (including presbyopia correction), myopia control and provision of optical products and services, the costs for which are currently not covered by public health insurance programs. Our basic ophthalmic services include treatments of a wide range of common eye diseases, including cataract, glaucoma, squint, ocular fundus diseases, ocular surface diseases, orbital diseases and pediatric eye diseases, the cost of which are generally eligible to be covered by public health insurance programs. There is no overlap in the scope of the services provided and the diseases and corresponding treatments covered by our basic ophthalmic services and consumer ophthalmic services. In light of upgraded social consumption in China over the recent years, we plan to increase our strategic focus on our consumer ophthalmic services business and devote more efforts to pursue a continued rapid growth, while maintaining the fundamental strength of our basic ophthalmic business. We have a deep bench of ophthalmic experts with medical expertise and rich experience to treat a wide range of eye diseases and to provide various types of consumer ophthalmic services. We focus on the quality of our ophthalmic services and devote resources to allow our ophthalmologists to provide ophthalmic medical services in a professional, dedicated and responsible manner. We are also committed to recruiting and cultivating qualified professionals to form an ophthalmic medical team with outstanding professional and ethical standards and strong sense of responsibility. As of the Latest Practicable Date, our medical professional team consisted of 261 registered physicians (including 67 multi-site practice physicians who were not our full-time employees). Advanced technology and equipment is another key factor underpinning our market leadership. Our patients are treated by ophthalmologists with latest technology and advanced equipment. According to the Frost & Sullivan Report, we are the first-mover in Inner Mongolia to use micropulse laser technology to treat macular edema, to use minimally invasive vitreoretinal surgeries to treat vitreous and ocular fundus diseases, and to use artificial vitreous body implantations to protect the eye from atrophy. We are a leader in Inner Mongolia to first introduce advanced medical equipment, such as OPTOS ultra-widefield fundus imaging system, vitreous cutter, optical coherence tomography for blood flow quantification, microfield detector and corneal confocal microscopy. We believe that our Baotou Hospital is the one-and-only ophthalmic hospital in Inner Mongolia with a preparation room to produce hospital-made traditional Chinese medicine capsules and eye drops. In particular, we are one of the few medical service providers in China that are qualified to produce 0.01% atropine sulfate eye drops to be prescribed within the respective hospitals to control myopia among adolescents. We believe that our capabilities in hospital-made pharmaceuticals have helped improve our brand awareness and customer loyalty, brought us competitive advantage in the area of myopia control and increased our overall revenue. We experienced a rapid growth during the Track Record Period. Our revenue increased by 13.0% from RMB632.7 million in 2018 to RMB714.7 million in 2019, and further increased by 11.1% to RMB794.3 million in 2020. Our net profit also increased significantly from RMB29.2 million in 2018 to RMB70.8 million in 2019, and further increased by 70.2% to RMB120.5 million in 2020. In 2018, 2019 and 2020, our hospitals received 638,650 visits, 702,143 visits and 696,206 visits from our patients, and our optical centers received 73,935 visits, 79,903 visits and 91,660 visits from our customers, respectively. Source: Chaoju Eye Care (02219) Prospectus (IPO Date : 2021/06/24)
Listing Market	MAIN
Industry	Health Care Services
Background	Others
Major Business Area	N/A

Corporate Information

Substantial Shareholders	Zhang Bozhou (14.05%) Li Gabriel (12.01%) Zhang Xiaoli (11.93%) Zhang Junfeng (8.49%) Zhang Wenwen & Associates (5.05%)
Directors	Zhang Bozhou (Chairman and Chief Executive Officer and Executive Director) Zhang Guangdi (Executive Director) Zhang Junfeng (Executive Director) Zhang Xiaoli (Executive Director) Li Zhen (Non-Executive Director) Richard Chen Mao (Non-Executive Director) Zhang Li (Non-Executive Director) Bao Shan (Independent Non-Executive Director) Guo Hongyan (Independent Non-Executive Director) He Mingguang (Independent Non-Executive Director) Li Jianbin (Independent Non-Executive Director)
Company Secretary	Cheng Ching Kit Xie Chun
Principal Bankers
Solicitors	Jingtian & Gongcheng LLP
Auditors	Ernst & Young
Registered Office	Level 20, One International Finance Centre, 1 Harbour View Street, Central, Hong Kong
Share Registrars	Computershare Hong Kong Investor Services Ltd. [Tel: (852) 2862-8628]
Share Registrars Tel No	(852) 2862-8628
Internet Address	http://www.chaojueye.com
Email Address	[email protected]
Tel No	(86 10) 6336-8995
Fax No

SITEMAP

AASTOCKS.com

Members

Forgot Password

About Us

Email: [email protected]

AASTOCKS.COM LIMITED (阿斯達克網絡信息有限公司) All rights reserved.

Disclaimer

You expressly agree that the use of this app/website is at your sole risk.

AASTOCKS.com Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co. Ltd, Nasdaq, Inc., their respective holding companies and/or any subsidiaries of such holding companies, their Sources and/or other third party data provider(s) endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

Neither AASTOCKS.com Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co.Ltd., Nasdaq, Inc. nor their respective holding companies and/or any subsidiaries of such holding companies nor their Sources and/or other third party data provider(s) make any express or implied offers, representations or warranties (including, without limitation, any warranty or merchantability or fitness for a particular purpose or use) regarding the Information.

Neither AASTOCKS.com Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co. Ltd., Nasdaq, Inc. nor their respective holding companies and/or any subsidiaries of such holding companies nor their Sources and/or other third party data provider(s) will be liable to any Subscriber or any other party for any interruption, inaccuracy, error, or omission, regardless of cause, in the Information or for any damages (whether direct or indirect, consequential, punitive, or exemplary) resulting from its use by any party.

AASTOCKS.com Limited shall not be liable for any failure or delay in performance of its obligations under this Disclaimer because of circumstances beyond its reasonable control, including but without limitation, acts of God, typhoons, rainstorms, other natural disasters, government restrictions, strikes, wars, virus outbreak, network failures or telecommunications failures.

Morningstar Disclaimer: Copyright © 2020 Morningstar, Inc. All Rights Reserved. The information, data, analyses and opinions ("Information") contained herein: (1) include the proprietary information of Morningstar and Morningstar’s third party licensors; (2) may not be copied or redistributed except as specifically authorised; (3) do not constitute investment advice; (4) are provided solely for informational purposes; and (5) are not warranted to be complete, accurate or timely. Morningstar is not responsible for any trading decisions, damages or other losses related to the Information or its use. Please verify all of the Information before using it and don’t make any investment decision except upon the advice of a professional financial adviser. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up.

The information and contents contained in this app/website are based on the analyses and interpretations of publicly available information obtained from sources believed to be reliable. Such analyses and information have not been independently verified and AASTOCKS.com Limited makes no guarantees to their accuracy, completeness, timeliness or correctness.

The information, financial market data, quotes, charts, statistics, exchange rate, news, research, analysis, buy and sell ratings, Education Center and other information on this app/website should be used as references only at your own discretion. Prior to the execution of a security or any other trade based upon the Information, you are advised to consult independent professional advice to verify pricing information or to obtain more detailed market information. AASTOCKS.com Limited is not soliciting any subscriber or app/website visitor to execute any trade. Any trades executed following the said information, commentaries and/or buy/sell ratings on this app/website are taken at your own risk for your own account.

AASTOCKS.com Limited provides the information and services on an "AS IS" basis. The information and contents on this app/website are subject to change without notice. AASTOCKS.com Limited reserves the right, in its sole discretion but without any obligation, to make improvements to, or correct any error or omissions in any portion of this app/website at any time.

The subscriber or app/website visitor agrees not to reproduce, retransmit, disseminate, distribute, broadcast, publish, circulate, sell or commercially exploit the information and contents on this app/website in any manner without the express written consent of AASTOCKS.com Limited.

Investment involves risk. You may make use of the Education Center of this website for academic reference purposes at your own discretion. AASTOCKS.com Limited cannot and does not give any assurance that the present or future buy/sell commentaries and signals on this app/website will be profitable. AASTOCKS.com Limited cannot guarantee, and the subscriber or app/website visitor should not assume, that the future performance will equal past performance.

AASTOCKS.com Limited may point to other sites that may be of interest to the subscriber or app/website visitor but for which AASTOCKS.com Limited has no responsibility and only provides this as a service to the subscriber or app/website visitor.

AASTOCKS.com Limited does not represent or endorse the accuracy or reliability of any information, advertisements or contents contained on, distributed through, or linked, downloaded or accessed from any of the services on this app/website. AASTOCKS.com Limited cannot and does not guarantee the quality or reliability of any products or information purchased or obtained by you as a result of an advertisement or any other information displayed on this app/website.

AATV is a video platform owned by AASTOCKS.com Limited.

You acknowledge that: (i) AATV is provided for information purposes only and, in particular, is not intended for trading purposes; (ii) AATV does not and none of the information contained in its program constitutes a solicitation, offer, opinion, or recommendation by us to buy or sell any security, or to provide legal, tax, accounting, or investment advice or services whether or not regarding the profitability or suitability of any security or investment; and (iii) AATV is not intended for use by, or distribution to, any person or entity in any jurisdiction or country where such use or distribution would be contrary to law or regulation.

The financial analysis or opinion expressed in the AATV programs is for reference and discussion only, and does not represent AASTOCKS.com Limited. Investors must make their own investment decisions based on their own investment objectives and financial situation. AASTOCKS.com Limited shall not, directly or indirectly, be liable, in any way, to you or any other person for any: (i) inaccuracies or errors in or omissions from AATV including, but not limited to, quotes and financial data; (ii) delays, errors, or interruptions in the transmission or delivery of AATV; or (iii) loss or damage arising therefrom or occasioned thereby, or by any reason of nonperformance.

AASTOCKS.com Limited reserves the right to change this Disclaimer at any time by posting changes online at this app/website. You are responsible for reviewing regularly information posted therein to obtain timely notice of such changes. Your continued use of this app / website after changes are posted constitutes your acceptance of this Agreement as modified by the posted changes.

The disclaimer herein shall be governed by the law of the Hong Kong Special Administrative Region of the People's Republic of China ("Hong Kong") and you agree to submit to the exclusive jurisdiction of the Hong Kong courts.

In the event of any discrepancy between the Chinese and English versions, the English version shall prevail.

Last updated on 6 January 2023.